Global Cord Blood (NYSE:CO) Earns Strong-Buy Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Global Cord Blood (NYSE:CO) in a research note published on Friday morning. The brokerage issued a strong-buy rating on the medical research company’s stock.

Global Cord Blood Price Performance

NYSE CO opened at $1.01 on Friday. The firm has a market capitalization of $122.77 million, a PE ratio of 1.58 and a beta of 0.16. The company’s 50 day simple moving average is $1.19 and its 200 day simple moving average is $1.39. Global Cord Blood has a 12 month low of $2.03 and a 12 month high of $5.50.

Global Cord Blood Company Profile

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.